Charles River Laboratories insider trading
Health Care · Heavy sellingShare price and insider trades
Valuation, profit and volume
Summary
Over the past 12 months, 0 Charles River Laboratories insiders reported open-market purchases totaling $0, while 7 insiders reported sales totaling $42.7M. 7 of 19 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
News and SEC events
Recent 8-K filings and headlines. Tone is scored from the headline wording; “Policy” marks regulatory, trade or government topics.
- 8-K Investor disclosure
- 8-K Earnings release
Insider transactions
Open-market purchases and sales. 93 grants, option exercises and tax withholdings are not shown.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Oct 2SEC | Glenn ColemanCFO | Buy | 10 | $297.43 | $3K | +4.5% | — |
| Aug 27SEC | James C FosterDirector | Sell Plan | 33,561 | $300.00 | $10.1M | +3.6% | — |
| Aug 20SEC | Shannon M ParisottoCevp, Disc & Safety Assessment | Sell Plan | 2,039 | $294.12 | $600K | +5.7% | — |
| Aug 20SEC | Nancy C AndrewsDirector | Sell | 573 | $285.24 | $163K | +9.0% | — |
| Aug 13SEC | Birgit GirshickCEO | Sell Plan | 6,500 | $279.90 | $1.8M | +11.0% | — |
| Aug 13SEC | Shannon M ParisottoCevp, Disc & Safety Assessment | Sell Plan | 3,714 | $279.66 | $1.0M | +11.1% | — |
| Aug 11SEC | James C FosterDirector | Sell Plan | 28,733 | $275.00 | $7.9M | +13.0% | — |
| Aug 10SEC | Victoria L CreamerEvp & Chief People Officer | Sell | 4,179 | $259.16 | $1.1M | +19.9% | — |
| Aug 10SEC | Michael Gunnar KnellSvp, Finance And Cao | Sell | 1,274 | $259.07 | $330K | +20.0% | — |
| Aug 10SEC | Michael Gunnar KnellSvp, Finance And Cao | Sell | 1,205 | $258.53 | $312K | +20.2% | — |
| Aug 10SEC | Michael Gunnar KnellSvp, Finance And Cao | Sell | 901 | $260.63 | $235K | +19.2% | — |
| Aug 10SEC | Michael Gunnar KnellSvp, Finance And Cao | Sell | 810 | $261.45 | $212K | +18.9% | — |
| Aug 10SEC | Michael Gunnar KnellSvp, Finance And Cao | Sell | 736 | $258.53 | $190K | +20.2% | — |
| Aug 10SEC | Michael Gunnar KnellSvp, Finance And Cao | Sell | 620 | $263.94 | $164K | +17.7% | — |
| Aug 10SEC | Michael Gunnar KnellSvp, Finance And Cao | Sell | 482 | $265.17 | $128K | +17.2% | — |
| Aug 10SEC | Michael Gunnar KnellSvp, Finance And Cao | Sell | 404 | $258.53 | $104K | +20.2% | — |
| Aug 10SEC | Michael Gunnar KnellSvp, Finance And Cao | Sell | 213 | $262.37 | $56K | +18.4% | — |
| Aug 6SEC | Shannon M ParisottoCevp, Disc & Safety Assessment | Sell Plan | 5,046 | $263.00 | $1.3M | +18.2% | — |
| Jul 1SEC | James C FosterDirector | Sell Plan | 75,000 | $225.00 | $16.9M | +38.1% | — |
| Mar 4SEC | Joseph W LaplumeEvp, Corp Strategy & Develop | Buy | 25 | $174.54 | $4K | +78.1% | — |
| Jan 20SEC | Joseph W LaplumeEvp, Corp Strategy & Develop | Sell | 400 | $163.72 | $65K | +89.8% | — |
Insiders at Charles River Laboratories
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| James C FosterDirector | — | $34.8M | Aug 27, 2026 | — |
| Shannon M ParisottoCevp, Disc & Safety Assessment | — | $3.0M | Aug 20, 2026 | — |
| Birgit GirshickCEO | — | $1.8M | Aug 20, 2026 | — |
| Michael Gunnar KnellSvp, Finance And Cao | — | $1.7M | Aug 10, 2026 | — |
| Victoria L CreamerEvp & Chief People Officer | — | $1.1M | Aug 10, 2026 | — |
| Nancy C AndrewsDirector | — | $163K | Aug 20, 2026 | — |
| Joseph W LaplumeEvp, Corp Strategy & Develop | $4K | $65K | Aug 11, 2026 | — |
| Glenn ColemanCFO | $3K | — | Oct 2, 2026 | — |
| Steven BargDirector | — | — | Jun 3, 2026 | — |
| Mark MintzEvp, Chief Information Officer | — | — | Jun 2, 2026 | — |
| Paul W GravesDirector | — | — | May 12, 2026 | — |
| Craig B. ThompsonDirector | — | — | May 12, 2026 | — |
| Virginia M WilsonDirector | — | — | May 11, 2026 | — |
| Reshema Kemps-polancoDirector | — | — | May 11, 2026 | — |
| Mark J EnyedyDirector | — | — | May 11, 2026 | — |
| George Llado Sr.Director | — | — | May 11, 2026 | — |
| Martin MackayDirector | — | — | May 11, 2026 | — |
| Abraham CeesayDirector | — | — | May 11, 2026 | — |
Insider activity at other Health Care companies
Same sector, ranked by insider buying in the last 90 days.
Common questions about CRL insiders
Are Charles River Laboratories insiders buying CRL stock?
In the past 12 months, 0 insiders reported open-market purchases of CRL worth $0. The latest was CFO Glenn Coleman bought $3K of CRL at $297.43 — first open-market purchase in our records.
Are Charles River Laboratories insiders selling CRL stock?
7 insiders reported sales worth $42.7M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.